Wellington Regional Hospital
Welcome,         Profile    Billing    Logout  
 5 Trials 
32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Young, Paul
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
BoneZone, NCT04608630 / ACTRN12621000085875p: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
2
450
RoW
Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection
Australian and New Zealand Intensive Care Research Centre, Department of Health
Critical Illness, Osteoporosis
02/27
02/27
NCT06350734: Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

Recruiting
N/A
704
US
Non-Interventional Study
Mayo Clinic
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
01/29
01/29
TTM-2, NCT02908308: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

Completed
N/A
1900
Europe, US, RoW
Targeted temperature management to 33°C, Standard care with early treatment of fever
Helsingborgs Hospital, Lund University, Region Skåne - Skånevård SUND, Copenhagen Trial Unit, Center for Clinical Intervention Research, Clinical Trials Sweden, Forum South, Integrated Biobank of Luxembourg
Out-of-hospital Cardiac Arrest
06/22
12/22
NCT06207942: Stepcare Extended Follow-up Substudy

Recruiting
N/A
600
Europe, RoW
Feed back controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, The George Institute for Global Health, Australia, Copenhagen Trial Unit, Center for Clinical Intervention Research, Helsinki University Central Hospital
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain, Cognitive Impairment, Caregiver Burden
06/26
12/26
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23
STEPCARE, NCT05564754 / ACTRN12623001057673: Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Recruiting
N/A
3500
Europe, RoW
Feedback-controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, Lund, Sweden, Copenhagen Trial Unit, Center for Clinical Intervention Research, The George Institute for Global Health, Australia, HUS Helsinki University Hospitals, Helsinki, Finland, Medical Research Institute of New Zealand Rangahautia Te Ora, Wellington, New Zealand
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
12/25
06/26
O'Donnell, Anne E
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Completed
2
40
US
ARINA-1, Placebo
Renovion, Inc.
Non-cystic Fibrosis Bronchiectasis
02/24
02/24
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
PTK0796-NTM-20203, NCT04922554: Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Completed
2
66
US
Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets
Paratek Pharmaceuticals Inc
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
06/24
07/24
Lee, Sarah
Lighthouse III, NCT06658977: RolloverTreatment with Triumeq for People with ALS Following the Lighthouse II Trial

Not yet recruiting
3
70
RoW
Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
Macquarie University, Australia
Amyotrophic Lateral Sclerosis, ALS
12/26
12/26
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis

Active, not recruiting
3
390
Europe, RoW
Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo
Macquarie University, Australia, King's College London, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
08/26
08/26
NCT04272606: TXA in Spinal Fusion

Completed
2
123
US
Tranexamic Acid, Cyklokapron, Saline Solution, Visual Acuity Exam, Eye Exam, 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Catherine R. Olinger
Degenerative Disc Disease
06/23
06/23
LINKER-AL2, NCT06292780: A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Recruiting
1/2
220
Europe, US
Linvoseltamab, REGN5458
Regeneron Pharmaceuticals
Relapsed/Refractory Systemic Light Chain Amyloidosis
08/28
02/35
Wilkinson, Jonathan
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
Hooks, Darren
NCT05903170: Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation

Recruiting
N/A
100
RoW
360J LifePak Monitor/Defibrillator, 200J Philips HeartStart MRx Monitor/Defibrillator
Wellington Hospital
Atrial Fibrillation
05/26
08/26
Bock, martin de
ACTRN12614001198617: Insulin pump therapy for adolescents with type 1 diabetes and poor glycaemic control

Active, not recruiting
4
10
 
Martin de Bock, Princess Margaret Hospital Foundation
Type 1 diabetes
 
 
NCT02748018: Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

Active, not recruiting
N/A
280
Europe, Canada, US, RoW
670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
Medtronic Diabetes
Type 1 Diabetes
03/25
06/25
NCT06428591: Tandem Freedom - Feasibility Trial 1

Completed
N/A
10
RoW
t:slim X2 insulin pump with Tandem Freedom Algorithm
Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1
06/24
06/24
NCT06547918: SmartAdjust 2.0 System With Type 1 and Type 2 Diabetes

Recruiting
N/A
75
RoW
Omnipod 5 SA2.0 System
Insulet Corporation
Diabetes Mellitus
04/25
08/25
ACTRN12617001294347p: The function and usability of two hybrid closed loop systems in patients aged 13 - 25 years with type 1 diabetes during a 7 day hotel study.

Not yet recruiting
N/A
12
 
princess Margaret Hospital, NHMRC
Type 1 diabetes
 
 
ACTRN12617001294347: The function and usability of two hybrid closed loop systems in patients aged 13 - 25 years with type 1 diabetes during a 7 day hotel study.

Not yet recruiting
N/A
12
 
princess Margaret Hospital, NHMRC, Juvenile Diabetes Research Foundation
Type 1 diabetes
 
 
ACTRN12621000360819: Optimizing outcomes in Advanced hybrid closed loop in children and adults with type 1 diabetes aged 2-80

Not yet recruiting
N/A
65
 
University of Otago , Otago Medical Research Foundation, Medtronic Diabetes
Type 1 Diabetes , Poor Glycaemic Control
 
 
ACTRN12620000034932p: Assessing efficacy and safety of Automated Insulin Delivery utilizing open source technology in children and adults with Type 1 Diabetes

Not yet recruiting
N/A
100
 
University of Otago, Health Research Council of New Zealand
Type 1 Diabetes
 
 
ACTRN12620000034932: Assessing efficacy and safety of Automated Insulin Delivery utilizing open source technology in children and adults with Type 1 Diabetes

Completed
N/A
100
 
University of Otago, Health Research Council of New Zealand
Type 1 Diabetes
 
 
ACTRN12621000889853: Glycaemic outcomes in people with type 2 diabetes initiating continuous glucose monitoring: The 2GO-CGM study

Active, not recruiting
N/A
80
 
University of Otago, DexCom, Inc.
Type 2 diabetes
 
 
ACTRN12622000190707: Feasibility study to assess a new Dexcom algorithm for fully automated insulin delivery in adults with diabetes

Completed
N/A
40
 
University of Otago, DexCom, Inc.
Type 1 diabetes mellitus, Type 2 diabetes mellitus
 
 
Gundersen, Sally J
PROTECTMe, NCT05651347: Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction

Recruiting
3
336
RoW
Placebo, Melatonin 10 MG
Monash University, National Health and Medical Research Council, Australia, Cerebral Palsy Alliance, Equity Trustees
Fetal Growth Retardation, Stillbirth and Fetal Death, Pregnancy Preterm
12/25
01/26
Joshi, Purwa
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis

Active, not recruiting
3
390
Europe, RoW
Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo
Macquarie University, Australia, King's College London, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
08/26
08/26
Plant, Allan
NCT05903170: Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation

Recruiting
N/A
100
RoW
360J LifePak Monitor/Defibrillator, 200J Philips HeartStart MRx Monitor/Defibrillator
Wellington Hospital
Atrial Fibrillation
05/26
08/26
Middleditch, Diane
NCT06117150: Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)

Recruiting
1
10
RoW
Drug-eluting Coronary Spur Stent System
ReFlow Medical, Inc.
In-stent Restenosis
10/24
11/25

Download Options